Table 1 Baseline Demographic, clinical and laboratory characteristics of patients.

n

134

61

73

 Female, n (%)

58 (43.3)

24 (39.3)

34 (46.6)

0.40

 Male, n (%)

76 (56.7)

37 (60.7)

39 (53.4)

Age, yr, median

67.2

69.1

66.2

0.125

 Range

40.2–86.6

47.7–83.3

40.2–86.6

Lines of therapy, (median, range)

5

5

4

0.0135

3–13

3–13

3–9

Len refractory n (%)

114 (85.0)

59 (96.7)

70 (96.7)

0.5

CRP, mg/L, (median, range)

7.1

6.7

10.5

0.1390

3.1–360

3.1–145.4

3.1–360

LDH, U/L, (median, range)

208.5

209

207

0.649

119–2082

142–2082

119–471

Ferritin, µg/L, (median, range)

186

157

239

0.3812

8–11290

13–11290

8–5616

Β₂-microglobulin, μg/dL (median, range)

3.28

4.09

3.05

0.1275

1.15–6.15

1.6–6.03

1.15 -6.15

Bone marrow plasma cells, (%)

(median, range)

10.5

0–100

15

0–100

9

0–95

0.9268

Plasma cell labeling index, (%)

(median, range)

2.7

0.1–20.6

2.6

0.2–20.6

3.0

0.1–15.1

0.7836

High risk cytogenetics, n/N;

(%)

81/107

(75.7)

39/53 (73.6)

42/54

(77.8)

0.613

Extramedullary disease, n/N;

(%)

27/106

(23.3)

16/58

(27.6)

11/48

(19.0)

0.2709